Abstract
Tissue-resident memory T (TRM) cells play a central role in immune responses to pathogens across all barrier tissues after infection. However, the underlying mechanisms that drive TRM differentiation and priming for their recall effector function remains unclear. In this study, we leveraged both newly generated and publicly available single-cell RNA-sequencing (scRNAseq) data generated across 10 developmental time points to define features of CD8 TRM across both skin and small-intestine intraepithelial lymphocytes (siIEL). We employed linear modeling to capture temporally-associated gene programs that increase their expression levels in T cell subsets transitioning from an effector to a memory T cell state. In addition to capturing tissue-specific gene programs, we defined a consensus TRM signature of 60 genes across skin and siIEL that can effectively distinguish TRM from circulating T cell populations, providing a more specific TRM signature than what was previously generated by comparing bulk TRM to naïve or non-tissue resident memory populations. This updated TRM signature included the AP-1 transcription factor family members Fos, Fosb and Fosl2. Moreover, ATACseq analysis detected an enrichment of AP-1-specific motifs at open chromatin sites in mature TRM. CyCIF tissue imaging detected nuclear co-localization of AP-1 members Fosb and Junb in resting CD8 TRM >100 days post-infection. Taken together, these results reveal a critical role of AP-1 transcription factor members in TRM biology and suggests a novel mechanism for rapid reactivation of resting TRM in tissue upon antigen encounter.
Competing Interest Statement
Dr. Alexandra-Chole Villani has a financial interest in 10X Genomics. The company designs and manufactures gene sequencing technology for use in research, and such technology is being used in this research. Dr. Villanis interests were reviewed by The Massachusetts General Hospital and Mass General Brigham in accordance with their institutional policies. Dr. Thomas Kupper is an unpaid scientific advisor for Pellis Therapeutics, a company that works on vaccines. Dr. Peter K. Sorger is a member of the SAB or BOD of Rarecyte, Nanostring, Applied Biomath, Glencoe Software and Montai Health; he is consultant for Merck.